Russian Journal of Bioorganic Chemistry (ISSN: 1068-1620, E-ISSN: 1608-330X), published by MAIK Nauka/Interperiodica/Springer, serves as a vital resource for researchers and professionals in the fields of bioorganic chemistry, biochemistry, and organic chemistry. With a focus on the integration of organic chemistry principles with biological processes, this journal aims to disseminate significant findings and advancements from both theoretical and practical perspectives. Although currently not open access, the journal retains a dedication to high-quality, peer-reviewed content, contributing to its reputation within the academic community. The 2023 Scopus rankings position it within the Q4 category for both biochemistry and organic chemistry, indicating its critical niche within these disciplines amid a competitive landscape. Since its inception in 1996, the journal has continued to evolve, providing enriching insights and fostering collaborations among scholars and practitioners alike, with publication converging up to the year 2024. By exploring complex biomolecular interactions and the synthesis of biologically relevant compounds, the Russian Journal of Bioorganic Chemistry remains a significant platform for advancing knowledge and innovation in the life sciences.

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.

Comparative Immunology Microbiology and Infectious Diseases, published by Elsevier Science Ltd, is a prominent journal dedicated to advancing the fields of immunology, microbiology, infectious diseases, and veterinary sciences. Established in 1978, this journal has become a vital resource for researchers and professionals alike, with a commendable impact factor that reflects its significance in academia. The journal, available in both print and electronic formats (ISSN: 0147-9571, E-ISSN: 1878-1667), stands out for its commitment to disseminating innovative research findings, particularly through its categorization in Q2 and Q3 quartiles across various related disciplines as of 2023. The journal aims to provide insightful comparative analyses that enhance our understanding of host-pathogen interactions, immune responses, and disease manifestations. With a global readership base, it serves as a platform for collaborative discourse among scientists and professionals, ultimately contributing to the improvement of health outcomes worldwide.

Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.

Reviews and Research in Medical Microbiology is a premier academic journal published by LIPPINCOTT WILLIAMS & WILKINS, focusing on groundbreaking research and comprehensive reviews that advance the understanding of medical microbiology. With an ISSN of 2770-3150 and an E-ISSN of 2770-3169, this journal serves as an essential resource for researchers, healthcare professionals, and students dedicated to the study of pathogens, infectious diseases, and microbial mechanisms affecting health. While the journal currently does not offer open access, its rigorous peer-review process ensures that only high-quality, impactful research is disseminated to the scientific community. The journal aims to bridge gaps in knowledge by presenting cutting-edge studies that explore novel therapeutic strategies, diagnostic methods, and the evolving landscape of microbial resistance. Nestled in the heart of Philadelphia, this journal proudly contributes to the advancement of medical microbiology and is an indispensable platform for the publication of critical findings that shape clinical practices and research trajectories in the field.

Pathogens is a leading open-access journal published by MDPI since 2012, dedicated to advancing the understanding of infectious agents and their interactions with hosts in the fields of immunology, microbiology, and molecular biology. Based in Switzerland, this journal plays a crucial role in disseminating high-quality research that spans from fundamental studies of pathogen biology to the implications for global health and disease management. With a commendable impact factor and prestigious Q2 rankings across multiple categories—including Immunology and Microbiology—Pathogens ensures visibility and accessibility for groundbreaking findings. The journal embraces the ethos of open access, allowing researchers, professionals, and students to access critical research anytime, facilitating a collaborative and innovative academic environment. By bridging the gap between research and application, Pathogens is instrumental in shaping the future of infectious disease research and management.

CHEMICO-BIOLOGICAL INTERACTIONS is a premier journal published by Elsevier Ireland Ltd, dedicated to advancing the field of chemical and biological interactions since its inception in 1969. With a robust focus on pharmacology and toxicology, the journal holds a prestigious Q1 ranking in both Medicine (miscellaneous) and Toxicology, reflecting its significance in disseminating influential research. As part of the Scopus database, it ranks #21 out of 133 journals in Toxicology, positioning it in the 84th percentile and ensuring high visibility for cutting-edge studies. This scholarly platform serves as a crucial resource for researchers, professionals, and students who seek reliable and innovative findings at the intersection of chemistry and biology. While currently not open access, CHEMICO-BIOLOGICAL INTERACTIONS provides a comprehensive collection of articles that contribute to the ongoing dialogue in toxin research and its implications on medicinal chemistry, thereby fostering advancements in public health and safety.

ACS Infectious Diseases is a premier journal in the field of infectious diseases, published by the American Chemical Society. With an impressive Impact Factor that places it in the Q1 category for Infectious Diseases in 2023, the journal serves as an essential resource for researchers, healthcare professionals, and students dedicated to the study of infectious agents and their impact on public health. Established in 2015, the journal is committed to publishing cutting-edge research that enhances our understanding of infectious diseases and fosters the development of innovative interventions. Although not an open access journal, it provides a platform for high-quality research that influences policies and practices in the field. With an address located at 1155 16TH ST, NW, WASHINGTON, DC 20036, ACS Infectious Diseases is an authoritative voice in advancing the science and practice of infectious disease management.